Research progress in drugs targeting 5-lipoxygenase for age-related diseases.
- Author:
Zhi-Jun LI
1
;
Yan-Hui MA
1
;
Xi-Xi HOU
2
;
Tuan-Li YAO
3
;
Xiang-Yang QIN
4
Author Information
1. School of Chemistry and Chemical Engineering, Shaanxi University of Science and Technology, Xi'an 710021, China.
2. College of Life Science, Northwestern University, Xi'an 710068, China.
3. School of Chemistry and Chemical Engineering, Shaanxi University of Science and Technology, Xi'an 710021, China. yaotuanli@sust.edu.cn.
4. Department of Chemistry, School of Pharmacy, Air Force Medical University, Xi'an 710032, China. qinxiangyang@fmmu.edu.cn.
- Publication Type:Journal Article
- MeSH:
Humans;
Arachidonate 5-Lipoxygenase;
Leukotrienes;
Arachidonic Acid;
Aging;
Lipoxygenase Inhibitors/pharmacology*
- From:
Acta Physiologica Sinica
2023;75(6):864-876
- CountryChina
- Language:Chinese
-
Abstract:
With the acceleration of aging society, delaying aging or promoting healthy aging has become a major demand for human health. 5-Lipoxygenase (5-LOX) is a key enzyme catalyzing arachidonic acid into leukotrienes (LTs), which is a potent mediator of the inflammatory response. Previous studies showed that abnormal activation of 5-LOX and overproduction of LTs are closely related to the occurrence and development of aging-related inflammatory diseases. Therefore, inhibiting 5-LOX activation is a possibly potential strategy for treating age-related diseases. In this paper, the latest research progress in 5-LOX activation, 5-LOX in mediating aging-related diseases and its small molecule inhibitors is briefly reviewed to provide scientific theoretical basis and new ideas for the prevention and treatment of aging-related inflammatory diseases.
